@cellaritybio@MITdeptofBE@uwgenome@Novartis Thank you, @cellaritybio, for featuring our NRF2 program as part of your third annual symposium!
Watch @JoeyAzofeifa 's presentation: “Massively high throughput transcriptomics discovers a molecular glue degrading NRF2 in lung cancer” at 12:45 ET. https://t.co/XXugftaWdp
We’re also very excited to present our NRF2 degrader at @AACR! This amazing small molecule leads to regression of aggressive lung adenocarcinoma tumors in vivo and was discovered using our AI + transcriptomics platform.
Stop by on April 8th from 1:30-5:00, Section 52, Board 15.
Strong Arpeggio representation at @SLAS_Org with Tim Read and Casey Pham both presenting today in collaboration with @BCILifeSciences and @Biosero 👏
Be sure to connect with our team if you're there!
@davisidarta@humancellatlas Doesn't this make sense given that gene expression and the information content of genes is non-uniformally distributed? The top 500 most variable / highest-expressed are also going to be the most compressable, so PCA should do this? Lmk if I am missthinking this :)
Many professional biotech investors and operators think that rare disease parents are just a bunch of moms and dads who could never become biotech CEOs.
It’s true that most parents aren’t founders. But some are!
And when lightning strikes them, they go to work finding cures.
We are proud to be selected by the @endpts editorial team as one of the most promising and ambitious #biotech startups! We’re grateful for the recognition of what we’ve built so far and where we are headed next: the clinic in 2024! https://t.co/TttvLvamgu
I am increasingly -tive biotech.
(Consistent for past 3 years)
Investors are creating their own problems. They do not want to take risks on novel science. Instead supporting IPOs of me-too drugs and targets. Then they are left with a sea of competition with marginal benefit.
Human trampling affects alpine plants differently, which has important conservation implications 🌱🦶🏔️Delighted to share my first publication from my @snsf_ch postdoctoral fellowship!https://t.co/OFWVFvas6E
How inspiring that we've made @Norrsken's Impact100, an annual list of the world's 100 most promising impact #startups - this list exists to give you energy, hope, and positive inspiration! #100waystofixthefuture#NASDAQ
@RecursionChris Any advise on hiring senior executives. Especially those with significant pharma discovery/development experience. Green flags and red flags to look out for as to whether they would integrate well with a TechBio platform company culture! Thank you very much!!
We’re incredibly excited to publish the inaugural edition of the Decoding Bio Snapshot. Several months in the making, it profiles 40 companies operating at the intersection of computation and biology, ranging from pre-seed to publicly traded.
https://t.co/SQox37tUVq
Our CEO, @JoeyAzofeifa, will be talking at the BIO International Convention about how we're developing therapies for diseases driven by transcription factors! Please check out his talk on Wednesday June 7th at 4:15p ET in Room 104B! #StandUpForScience#BIO2023
It’s important – personally as well as professionally – not to put people on a pedestal. When we assume person X or Y has had so much success that they couldn’t possibly want to talk to *us*, we subtly rob them of their humanity. Everyone is more than the net sum of their...1/9